Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
EBioMedicine ; 78: 103956, 2022 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-35325780

RESUMO

BACKGROUND: The BCN02-trial combined therapeutic vaccination with a viral latency reversing agent (romidepsin, RMD) in HIV-1-infected individuals and included a monitored antiretroviral pause (MAP) as an efficacy read-out identifying individuals with an early or late (< or > 4weeks) viral-rebound. Integrated -omics analyses were applied prior treatment interruption to identify markers of virus control during MAP. METHODS: PBMC, whole-genome DNA methylation and transcriptomics were assessed in 14 BCN02 participants, including 8 Early and 4 Late viral-rebound individuals. Chromatin state, histone marks and integration analysis (histone-3 acetylation (H3Ac), viral load, proviral levels and HIV-specific T cells responses) were included. REDUC-trial samples (n = 5) were included as a control group for RMD administration alone. FINDINGS: DNA methylation imprints after receiving the complete intervention discriminated Early versus Late viral-rebound individuals before MAP. Also, differential chromatin accessibility and histone marks at DNA methylation level were detected. Importantly, the differential DNA methylation positions (DMPs) between Early and Late rebounders before MAP were strongly associated with viral load, proviral levels as well as the HIV-specific T-cell responses. Most of these DMPs were already present prior to the intervention and accentuated after RMD infusion. INTERPRETATION: This study identifies host DNA methylation profiles and epigenetic cascades that are predictive of subsequent virus control in a kick-and-kill HIV cure strategy. FUNDING: European Union Horizon 2020 Framework Programme for Research and Innovation under Grant Agreement N°681137-EAVI2020 and N°847943-MISTRAL, the Ministerio de Ciencia e Innovación (SAF2017_89726_R), and the National Institutes of Health-National Institute of Allergy and Infectious Diseases Program Grant P01-AI131568.


Assuntos
Infecções por HIV , Vacinas , Antirretrovirais/uso terapêutico , Linfócitos T CD4-Positivos , Cromatina , Epigênese Genética , Infecções por HIV/tratamento farmacológico , Infecções por HIV/genética , Humanos , Leucócitos Mononucleares , Provírus , Vacinas/uso terapêutico , Carga Viral
2.
Front Immunol ; 12: 657162, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34040607

RESUMO

The identification of new biomarkers is essential to predict responsiveness to vaccines. We investigated the whole-blood transcriptome and microbiome prior to immunization, in order to assess their involvement in induction of humoral responses two months later. We based our analyses on stool and skin microbiota, and blood transcriptome prior to immunization, in a randomized clinical study in which participants were vaccinated with the MVA-HIV clade B vaccine (MVA-B). We found that the levels of neutralizing antibody responses were correlated with abundance of Eubacterium in stool and Prevotella in skin. In addition, genus diversity and bacterial species abundance were also correlated with the expression of genes involved in B cell development prior to immunization and forecast strong responders to MVA-B. To our knowledge, this is the first study integrating host blood gene expression and microbiota that might open an avenue of research in this field and to optimize vaccination strategies and predict responsiveness to vaccines.


Assuntos
Interações entre Hospedeiro e Microrganismos/genética , Interações entre Hospedeiro e Microrganismos/imunologia , Imunidade Humoral , Microbiota , Transcriptoma , Vacinas/imunologia , Adolescente , Adulto , Anticorpos Neutralizantes/imunologia , Biodiversidade , Biomarcadores , Feminino , Humanos , Masculino , Metagenoma , Metagenômica/métodos , Pessoa de Meia-Idade , Vacinação , Adulto Jovem
3.
Front Immunol ; 11: 586124, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33244316

RESUMO

Background: Our previous work has demonstrated the benefits of transcutaneous immunization in targeting Langerhans cells and preferentially inducing CD8 T-cell responses. Methods: In this randomized phase Ib clinical trial including 20 HIV uninfected volunteers, we compared the safety and immunogenicity of the MVA recombinant vaccine expressing HIV-B antigen (MVA-B) by transcutaneous and intramuscular routes. We hypothesized that the quality of innate and adaptive immunity differs according to the route of immunization and explored the quality of the vector vaccine-induced immune responses. We also investigated the early blood transcriptome and serum cytokine levels to identify innate events correlated with the strength and quality of adaptive immunity. Results: We demonstrate that MVA-B vaccine is safe by both routes, but that the quality and intensity of both innate and adaptive immunity differ significantly. Transcutaneous vaccination promoted CD8 responses in the absence of antibodies and slightly affected gene expression, involving mainly genes associated with metabolic pathways. Intramuscular vaccination, on the other hand, drove robust changes in the expression of genes involved in IL-6 and interferon signalling pathways, mainly those associated with humoral responses, and also some levels of CD8 response. Conclusion: Thus, vaccine delivery route perturbs early innate responses that shape the quality of adaptive immunity. Clinical Trial Registration: http://ClinicalTrials.gov, identifier PER-073-13.


Assuntos
Vacinas contra a AIDS/administração & dosagem , Vacinas contra a AIDS/imunologia , Vacinas Virais/administração & dosagem , Vacinas Virais/imunologia , Vacinas contra a AIDS/efeitos adversos , Administração Cutânea , Anticorpos Antivirais/imunologia , Anticorpos Anti-HIV/imunologia , HIV-1 , Humanos , Imunidade Celular/imunologia , Injeções Intramusculares , Vacinação/métodos , Vacinas de DNA , Vacinas Sintéticas/imunologia , Vacinas Virais/efeitos adversos
4.
Med Sci (Paris) ; 36(1): 31-37, 2020 Jan.
Artigo em Francês | MEDLINE | ID: mdl-32014095

RESUMO

Vaccination is one of the major public health advances in modern medicine. But in order to improve the effectiveness of existing vaccines and develop new ones, we need to know more about the mechanisms of action that lead to protective immunity and the strategies that lead to sustainable defence. Cutaneous vaccination is a promising procedure because of the richness of innate cells in the skin and their role in the quality, intensity and persistence of adaptive responses. A Systems Biology approach is used to probe immunological dynamic post-vaccination and to simultaneously analyse a large number of variables: antibody and cytokines levels, gene expression or even cellular outcomes. Immunological data have been collected from an influenza vaccination clinical trial and, thanks to this approach, provided insight into the impact of the immunization route on the quality of immune responses. An innate gene signature is also identified in order to predict the intensity of immune responses.


TITLE: Prédire la réponse à la vaccination contre la grippe - Vers l'identification d'une signature moléculaire précoce. ABSTRACT: La vaccination est l'un des progrès majeurs de la médecine moderne. Mais afin d'améliorer l'efficacité des vaccins existants et d'en élaborer de nouveaux, nous devons mieux connaître les mécanismes d'action à l'origine de l'immunité protectrice et les stratégies vaccinales permettant d'induire une défense durable. La voie cutanée est une stratégie de vaccination importante, en raison de la richesse qu'elle présente en cellules de l'immunité innée qui ont un rôle clé dans la qualité, l'intensité et la persistance des réponses adaptatives qu'elles induisent. L'intégration des données biologiques obtenues au cours d'un essai clinique de vaccination antigrippale nous donne un aperçu de l'impact de la voie d'immunisation et de la signature innée sur la qualité des réponses immunitaires.


Assuntos
Vacinas contra Influenza/uso terapêutico , Influenza Humana/genética , Influenza Humana/prevenção & controle , Transcriptoma , Vacinação , Diagnóstico Precoce , Humanos , Influenza Humana/diagnóstico , Influenza Humana/imunologia , Técnicas de Diagnóstico Molecular , Prognóstico , Resultado do Tratamento
5.
J Proteomics ; 216: 103670, 2020 03 30.
Artigo em Inglês | MEDLINE | ID: mdl-31991189

RESUMO

The skin plays a crucial role in host defences against microbial attack and the innate cells must provide the immune system with sufficient information to organize these defences. This unique feature makes the skin a promising site for vaccine administration. Although cellular innate immune events during vaccination have been widely studied, initial events remain poorly understood. Our aim is to determine molecular biomarkers of skin innate reaction after intradermal (i.d.) immunization. Using an ex vivo human explant model from healthy donors, we investigated by NanoLC-MS/MS analysis and MALDI-MSI imaging, to detect innate molecular events (lipids, metabolites, proteins) few hours after i.d. administration of seasonal trivalent influenza vaccine (TIV). This multimodel approach allowed to identify early molecules differentially expressed in dermal and epidermal layers at 4 and 18 h after TIV immunization compared with control PBS. In the dermis, the most relevant network of proteins upregulated were related to cell-to-cell signalling and cell trafficking. The molecular signatures detected were associated with chemokines such as CXCL8, a chemoattractant of neutrophils. In the epidermis, the most relevant networks were associated with activation of antigen-presenting cells and related to CXCL10. Our study proposes a novel step-forward approach to identify biomarkers of skin innate reaction. SIGNIFICANCE: To our knowledge, there is no study analyzing innate molecular reaction to vaccines at the site of skin immunization. What is known on skin reaction is based on macroscopic (erythema, redness…), microscopic (epidermal and dermal tissues) and cellular events (inflammatory cell infiltrate). Therefore, we propose a multimodal approach to analyze molecular events at the site of vaccine injection on skin tissue. We identified early molecular networks involved biological functions such cell migration, cell-to-cell interaction and antigen presentation, validated by chemokine expression, in the epidermis and dermis, then could be used as early indicator of success in immunization.


Assuntos
Vacinas contra Influenza , Influenza Humana , Humanos , Vacinas contra Influenza/efeitos adversos , Influenza Humana/prevenção & controle , Injeções Intradérmicas , Estações do Ano , Espectrometria de Massas em Tandem , Vacinação/efeitos adversos
6.
J Clin Invest ; 129(5): 1960-1971, 2019 05 01.
Artigo em Inglês | MEDLINE | ID: mdl-30843873

RESUMO

BACKGROUND: Systems vaccinology allows cutting-edge analysis of innate biomarkers of vaccine efficacy. We have been exploring novel strategies to shape the adaptive immune response, by targeting innate immune cells through novel immunization routes. METHODS: This randomized phase I/II clinical study (n=60 healthy subjects aged 18-45 years old) used transcriptomic analysis to discover early biomarkers of immune response quality after transcutaneous (t.c.), intradermal (i.d.), and intramuscular (i.m.) administration of a trivalent influenza vaccine (TIV season 2012-2013) (1:1:1 ratio). Safety and immunogenicity (hemagglutinin inhibition (HI), microneutralization (MN) antibodies and CD4, CD8 effector T cells) were measured at baseline Day (D)0 and at D21. Blood transcriptome was analyzed at D0 and D1. RESULTS: TIV-specific CD8+GranzymeB+(GRZ) T cells appeared in more individuals immunized by the t.c. and i.d. routes, while immunization by the i.d. and i.m. routes prompted high levels of HI antibody titers and MN against A/H1N1 and A/H3N2 influenza viral strains. The early innate gene signature anticipated immunological outcome by discriminating two clusters of individuals with either distinct humoral or CD8 cytotoxic responses. Several pathways explained this dichotomy confirmed by nine genes and serum level of CXCL10 were correlated with either TIV-specific cytotoxic CD8+GRZ+ T-cell or antibody responses. A logistic regression analysis demonstrated that these nine genes and serum levels of CXCL10 (D1/D0) best foreseen TIV-specific CD8+GRZ+ T-cell and antibody responses at D21. CONCLUSION: This study provides new insight into the impact of immunization routes and innate signature in the quality of adaptive immune responses.


Assuntos
Imunidade Humoral , Vacinas contra Influenza/imunologia , Linfócitos T Citotóxicos/imunologia , Adolescente , Adulto , Anticorpos Antivirais/imunologia , Formação de Anticorpos , Linfócitos T CD8-Positivos/citologia , Quimiocina CXCL10/metabolismo , Feminino , Perfilação da Expressão Gênica , Granzimas/metabolismo , Humanos , Imunidade Celular , Vírus da Influenza A Subtipo H1N1/imunologia , Vírus da Influenza A Subtipo H3N2/imunologia , Influenza Humana/imunologia , Influenza Humana/prevenção & controle , Masculino , Pessoa de Meia-Idade , Transcriptoma , Vacinação , Adulto Jovem
7.
J Exp Med ; 215(10): 2536-2553, 2018 10 01.
Artigo em Inglês | MEDLINE | ID: mdl-30201786

RESUMO

Tissue-resident macrophages can self-maintain without contribution of adult hematopoiesis. Herein we show that tissue-resident interstitial macrophages (Res-TAMs) in mouse lungs contribute to the pool of tumor-associated macrophages (TAMs) together with CCR2-dependent recruited macrophages (MoD-TAMs). Res-TAMs largely correlated with tumor cell growth in vivo, while MoD-TAMs accumulation was associated with enhanced tumor spreading. Both cell subsets were depleted after chemotherapy, but MoD-TAMs rapidly recovered and performed phagocytosis-mediated tumor clearance. Interestingly, anti-VEGF treatment combined with chemotherapy inhibited both Res and Mod-TAM reconstitution without affecting monocyte infiltration and improved its efficacy. Our results reveal that the developmental origin of TAMs dictates their relative distribution, function, and response to cancer therapies in lung tumors.


Assuntos
Neoplasias Pulmonares/imunologia , Macrófagos/imunologia , Monócitos/imunologia , Fagocitose , Animais , Neoplasias Pulmonares/patologia , Macrófagos/patologia , Camundongos , Camundongos Knockout , Monócitos/patologia , Receptores CCR2/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...